

**IN THE CLAIMS:**

Please amend the claims as follows:

1. (canceled).
2. (canceled).
3. (canceled).
4. (canceled).
5. (canceled).
6. (canceled).
7. (canceled).
8. (canceled).
9. (canceled).
10. (canceled).
11. (canceled).
12. (canceled).
13. (canceled).
14. (canceled).

15. (canceled).

16. (canceled).

17. (canceled).

18. (canceled).

19. (canceled).

20. (canceled).

21. (canceled).

22. (canceled).

23. (canceled).

24. (canceled).

25. (canceled).

26. (canceled).

27. (canceled).

28. (canceled).

29. (canceled).

30. (canceled).

31. (canceled).

32. (canceled).

33. (previously presented) A method of screening for and/or diagnosis or prognosis of carcinoma selected from breast, pancreatic, lung, bladder or kidney cancer or osteosarcoma in a subject, and/or monitoring the effectiveness of carcinoma therapy, which comprises the step of detecting and/or quantifying, in a biological sample selected from breast, pancreatic, lung, bladder, kidney or bone tissue obtained from said subject, a PTK7 polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:1.

34. (currently amended) The method of claim 33, wherein the ~~level of said~~ detected or quantified polypeptide is compared to a previously determined reference range or control.

35. (currently amended) The method according to claim 33, wherein the step of detecting comprises:

- (a) contacting the sample with a capture reagent that is specific for ~~[[a]]~~ said PTK7 polypeptide; and
- (b) detecting whether binding has occurred between the capture reagent and said polypeptide in the sample.

36. (previously presented) The method according to claim 35, wherein step (b) comprises detecting the captured polypeptide using a directly or indirectly labelled detection reagent.

37. (previously presented) The method according to claim 35, wherein the capture reagent is immobilised on a solid phase.

38. (currently amended) The method according to claim 34, wherein the step of detecting comprises:

- (a) contacting the sample with a capture reagent that is specific for [[a]] said PTK7 polypeptide; and
- (b) detecting whether binding has occurred between the capture reagent and said polypeptide in the sample.

39. (previously presented) The method according to claim 38, wherein step (b) comprises detecting the captured polypeptide using a directly or indirectly labelled detection reagent.

40. (previously presented) The method according to claim 36, wherein the capture reagent is immobilised on a solid phase.

41. (previously presented) The method according to claim 39, wherein the capture reagent is immobilised on a solid phase.

42. (previously presented) The method according to claim 35, wherein the capture reagent is an antibody that specifically binds to the PTK7 polypeptide.